Le Lézard
Classified in: Health, Science and technology
Subjects: SVY, BFA, FDA

Janssen Announces U.S. FDA Approval Of TREMFYAtm (Guselkumab) For The Treatment Of Moderate To Severe Plaque Psoriasis



HORSHAM, Pa., July 13, 2017 /PRNewswire/ -- Janssen Biotech, Inc.(Janssen) announced today that the U.S. Food and Drug Administration (FDA) has approved TREMFYAtm (guselkumab) for the treatment of adults living with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. TREMFYAtm is the first and only approved biologic therapy that selectively blocks only IL-23, a cytokine that plays a key role in plaque psoriasis. Approval comes after an expedited regulatory review following application of an FDA Priority Review Voucher. TREMFYAtm is administered as a 100 mg subcutaneous injection every eight weeks, following two starter doses at weeks 0 and 4. In clinical studies, patients receiving TREMFYAtm experienced significant improvement in skin clearance and greater improvement in symptoms of plaque psoriasis including itch, pain, stinging, burning and skin tightness when compared with placebo at week 16. Superior results in skin clearance (PASI 90) were demonstrated with TREMFYAtm compared with Humira® (adalimumab) at weeks 16, 24 and 48.

Experience the interactive Multichannel News Release here: https://www.multivu.com/players/English/8100151-janssen-fda-approval-tremfya-plaque-psoriasis/

"TREMFYAtm represents a significant milestone in the treatment of moderate to severe plaque psoriasis as evidenced by the proven skin clearance demonstrated in the majority of study patients receiving this IL-23?specific therapy at week 16 and up to week 48," said Andrew Blauvelt, M.D., M.B.A., President of Oregon Medical Research Center, and study investigator. "We continue to make progress in understanding the science of psoriasis and the important role IL-23 plays in the pathogenesis of this disease, which is another reason why today's approval of TREMFYAtm is exciting, both as a researcher and a practicing dermatologist."

"Living with plaque psoriasis is challenging, especially the constant pain, itching and burning," said Patti Janick, a guselkumab clinical trial participant. "I am encouraged by the results I've experienced with TREMFYAtm and the possibility it offers others living with plaque psoriasis to find similar relief and clearer skin."

TREMFYAtm received FDA approval based on results from a clinical development program that included more than 2,000 patients in the Phase 3 VOYAGE 1, VOYAGE 2 and NAVIGATE studies, which have been published in peer-reviewed journals and were presented at the 25th European Academy of Dermatology and Venerology Congress and the 2017 American Academy of Dermatology Annual Meeting.

"Addressing the need for additional safe and effective plaque psoriasis therapies has been a critical area of focus at Janssen for more than 15 years," said Andrew Greenspan, M.D., Vice President of Medical Affairs at Janssen. "Considering this, we applied a priority review voucher to the application for TREMFYAtm to bring this novel treatment to patients sooner."

"The approval of new and effective treatment options is always welcome news for the plaque psoriasis patient community, as not all patients respond similarly to currently available treatments," said Michael Siegel, Ph.D., Vice President of Research Programs for the National Psoriasis Foundation. "For the more than one million Americans living with moderate to severe plaque psoriasis, the approval of TREMFYAtm is a meaningful addition and offers physicians and patients an effective new, first-in-class therapy that selectively inhibits IL-23."

Janssen will work closely with payers, providers and pharmacy benefit managers to ensure TREMFYAtm is broadly accessible and affordable for patients and that the cost for payers is competitive with currently available biologic therapies for psoriasis. Janssen offers a number of patient support programs, including a co-pay card for patients with commercial insurance that reduces their out-of-pocket cost for TREMFYAtm to no more than $5 per dose.

Full Prescribing Information and Medication Guide will be available soon at www.tremfyahcp.com.  

Efficacy Evaluation
The TREMFYAtm versus placebo analysis is based on the results of an analysis of 101 global sites from VOYAGE 1 and 115 global sites from VOYAGE 2 (including North American sites [i.e., U.S. and Canada]).

*The TREMFYAtm versus Humira® analysis is based on the results of an analysis of 38 North American sites (U.S.=27, Canada=11) from VOYAGE 1 and 41 North American sites (U.S.=31, Canada=10) from VOYAGE 2 that utilized U.S.-licensed Humira®.

About TREMFYAtm (guselkumab)
TREMFYAtm is a human monoclonal antibody developed by Janssen that selectively blocks the protein interleukin (IL)-23 and is indicated for the treatment of adult patients with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet or UV light). A Phase 3 study evaluating TREMFYAtm in the treatment of active psoriatic arthritis is ongoing, and a Phase 3 program evaluating the efficacy of TREMFYAtm compared with Cosentyx® (secukinumab) in the treatment of moderate to severe plaque psoriasis is underway.

Applications seeking approval in the European Union, Japan and other countries are currently under review.

TREMFYAtm is a trademark of Janssen Biotech, Inc.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about TREMFYAtm?
TREMFYAtm may cause serious side effects, including infections. TREMFYAtm is a prescription medicine that may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with TREMFYAtm and may treat you for TB before you begin treatment with TREMFYAtm if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with TREMFYAtm.

?    fever, sweats, or chills                              ?    diarrhea or stomach pain
?    muscle aches                                             ?    shortness of breath
?    weight loss                                                ?    blood in your phlegm (mucus)
?    cough                                                        ?    burning when you urinate or
?    warm, red, or painful skin or sores                 urinating more often than normal
on your body different from your
psoriasis

Before using TREMFYAtm, tell your healthcare provider about all of your medical conditions, including if you:

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of TREMFYAtm?
TREMFYAtm may cause serious side effects. See "What is the most important information I should know about TREMFYAtm?"

The most common side effects of TREMFYAtm include: upper respiratory infections, headache, injection site reactions, joint pain (arthralgia), diarrhea, stomach flu (gastroenteritis), fungal skin infections, and herpes simplex infections.

These are not all the possible side effects of TREMFYAtm. Call your doctor for medical advice about side effects.

Use TREMFYAtm exactly as your healthcare provider tells you to use it.

Please read the full Prescribing Information, including Medication Guide for TREMFYAtm, and discuss any questions that you have with your doctor.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

075142-170622

About STELARA® (ustekinumab)
STELARA® is a human interleukin (IL)-12 and IL-23 antagonist indicated in the U.S. for the treatment of adult patients with: moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy; active psoriatic arthritis, alone or in combination with methotrexate; and moderately to severely active Crohn's disease who have failed or were intolerant to treatment with immunomodulators or corticosteroids but never failed treatment with a tumor necrosis factor (TNF) blocker, or who failed or were intolerant to treatment with one or more TNF blockers.

The Janssen Pharmaceutical Companies of Johnson & Johnson maintain exclusive worldwide marketing rights to STELARA®, which is currently approved for the treatment of moderate to severe plaque psoriasis in 89 countries, active psoriatic arthritis in 79 countries, pediatric psoriasis in 33 countries and moderately to severely active Crohn's disease in 32 countries.

IMPORTANT SAFETY INFORMATION 
STELARA® is a prescription medicine that affects your immune system. STELARA® can increase your chance of having serious side effects including:

Serious Infections 

STELARA® may lower your ability to fight infections and may increase your risk of infections. While taking STELARA®, some people have serious infections, which may require hospitalization, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses.

You should not start taking STELARA® if you have any kind of infection unless your doctor says it is okay.

Before starting STELARA®, tell your doctor if you:

After starting STELARA®, call your doctor right away if you have any symptoms of an infection (see above).

STELARA® can make you more likely to get infections or make an infection that you have worse. People who have a genetic problem where the body does not make any of the proteins interleukin 12 (IL?12) and interleukin 23 (IL?23) are at a higher risk for certain serious infections that can spread throughout the body and cause death. People who take STELARA® may also be more likely to get these infections.

Cancers 
STELARA® may decrease the activity of your immune system and increase your risk for certain types of cancer. Tell your doctor if you have ever had any type of cancer. Some people who had risk factors for skin cancer developed certain types of skin cancers while receiving STELARA®. Tell your doctor if you have any new skin growths.

Reversible posterior leukoencephalopathy syndrome (RPLS) 
RPLS is a rare condition that affects the brain and can cause death. The cause of RPLS is not known. If RPLS is found early and treated, most people recover. Tell your doctor right away if you have any new or worsening medical problems including: headache, seizures, confusion, and vision problems.

Serious Allergic Reactions 
Serious allergic reactions can occur. Stop using STELARA® and get medical help right away if you have any symptoms such as: feeling faint, swelling of your face, eyelids, tongue, or throat, chest tightness, or skin rash.

Before receiving STELARA®, tell your doctor if you:

Tell your doctor about all the medicines you take, including prescription and over?the?counter medicines, vitamins, and herbal supplements. Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.

When prescribed STELARA®:

Common side effects of STELARA® include: upper respiratory infections, headache, and tiredness in psoriasis patients; joint pain and nausea in psoriatic arthritis patients; and upper respiratory infections, redness at the injection site, vaginal yeast infections, itching, urinary tract infections, and vomiting in Crohn's disease patients. These are not all of the possible side effects with STELARA®. Tell your doctor about any side effect that you experience. Ask your doctor or pharmacist for more information.

Please read the full Prescribing Information and Medication Guide for STELARA® and discuss any questions you have with your doctor.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

About Psoriasis
Psoriasis is a chronic, autoimmune inflammatory disorder that results in the overproduction of skin cells, characterized by raised, inflamed, red lesions, or plaques, which can cause physical pain.1 It is estimated that more than 7.5 million Americans live with the disease.2 Approximately 80 percent of those affected with psoriasis have mild to moderate disease, while 20 percent have moderate to severe plaque psoriasis.2

About the Janssen Pharmaceutical Companies
At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it. Learn more at www.janssen.com. Follow us on Twitter at https://twitter.com/JanssenUS or https://twitter.com/JanssenGlobal.

Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding potential benefits and continued development of TREMFYAtm (guselkumab). The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Biotech, Inc. and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges inherent in product research and development, including the uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new products or new indications; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 1, 2017, including under "Item 1A. Risk Factors," its most recently filed Quarterly Report on Form 10-Q, including in the section captioned "Cautionary Note Regarding Forward-Looking Statements," and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Neither Janssen Biotech, Inc. nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

Humira® is a registered trademark of AbbVie Inc.
Cosentyx® is a registered trademark of Novartis.

References

  1. National Psoriasis Foundation. About Psoriasis. https://www.psoriasis.org/about-psoriasis. Accessed June 20, 2017.
  2. American Academy of Dermatology. Psoriasis. https://www.aad.org/media/stats/conditions/psoriasis Accessed June 20, 2017.

Media Contacts:

Investor Contacts:

Megan Farina

Lesley Fishman

610-724-1079

732-524-3922

mfarina@its.jnj.com

lfishma@its.jnj.com


Brian Kenney

Joseph J. Wolk

215-620-0111

732-524-1142

bkenney1@its.jnj.com

jwolk2@its.jnj.com

 

(PRNewsFoto/Janssen Biotech, Inc.)

 

SOURCE Janssen Biotech, Inc.


These press releases may also interest you

at 14:00
ORLANDO, Fla., Oct. 22, 2017 /PRNewswire/ -- Building on the success of its OnCommand® Connection remote diagnostics solution for all makes and models, Navistar announced that the OnCommand Connection Marketplace will go live on Friday, October 27,...

at 11:00
SAN DIEGO, Oct. 22, 2017 /PRNewswire/ -- ATA MC&E Booth #549 -- In advance of the Department of Transportation's (DOT) Electronic Logging Device (ELD) mandate, Lytx RAIR compliance services has added new functionality and a more streamlined workspace...

at 10:00
ATLANTA and WASHINGTON, Oct. 22, 2017 /PRNewswire/ -- LexisNexis Risk Solutions today announced at the International Association of Chiefs of Police (IACP) 2017 Conference that it has created a new Advisory Committee on policy and governance of its...

at 09:30
ATLANTA, Oct. 22, 2017 /PRNewswire/ -- To help law enforcement agencies be more successful with their field training officer programs from recruiting to evaluating officer performance, LexisNexis Risk Solutions will highlight its fully automated...

at 08:00
ORLANDO, Fla., Oct. 22, 2017 /PRNewswire/ -- SmartDrive Systems, a leader in video safety and transportation intelligence, today introduced SmartDrive SmartSensetm, a new line of intelligent driver-assist sensors designed to identify the most...

at 08:00
ORLANDO, Fla., Oct. 22, 2017 /PRNewswire/ -- SmartDrive Systems, a leader in video safety and transportation intelligence, today announced that Michelin North America has led a preferred-stock round of investment in the company. Michelin's investment...




News published on 13 july 2017 at 16:10 and distributed by: